A Phase 2 interventional study of Fulvestrant and Sapanisertib in Breast Neoplasms, sponsored by Calithera Biosciences, Inc. Completed at 53 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-08.
Sponsored by Calithera Biosciences, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose of this study is to compare the progression free survival (PFS) of participants treated with the combination of fulvestrant plus daily sapanisertib and fulvestrant plus weekly sapanisertib versus participants treated with single-agent fulvestrant.
The drug being tested in this study is called sapanisertib. Sapanisertib is being tested to treat postmenopausal women with advanced or metastatic estrogen receptor (ER) positive, human epidermal growth factor receptor-2 (HER2) negative breast cancer that has progressed during or after aromatase inhibitor (AI) therapy. This study will evaluate the efficacy and safety of combination of fulvestrant + daily sapanisertib and fulvestrant + weekly sapanisertib compared with fulvestrant alone.
The study will enroll approximately 153 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):
All participants will receive either fulvestrant 500 mg intramuscularly (IM), fulvestrant 500 mg + sapanisertib 4 mg daily or fulvestrant 500 mg + sapanisertib 30 mg weekly.
This multicenter trial will be conducted Spain and the USA. Participants will make multiple visits to the clinic, and end of treatment (EOT) visit which will occur 30 to 40 days after receiving their last dose of study drug or before the start of any subsequent anticancer therapy. After EOT, participants will be followed for progression free survival (PFS) and overall survival (OS).
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
This study's enrollment of 141 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Calithera Biosciences, Inc is the lead sponsor of 29 studies on the registry; none are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 10 (59%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
defined as either of the following:
Have a history of provided that all of the following criteria are met:
Clinical laboratory values as specified below within 4 weeks before the first dose of study drug:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fulvestrant 500 mg, intramuscularly (IM), once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 16.0 weeks).
Drug: Fulvestrant
Fulvestrant 500 mg, IM, once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle along with the sapanisertib 4 mg, capsules, orally, once daily in each 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 20.1 and 20.3 weeks for fulvestrant and sapanisertib respectively).
Drug: Fulvestrant · Drug: Sapanisertib
Fulvestrant 500 mg, IM, once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle along with sapanisertib 30 mg, capsule, orally, once weekly in each 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 17.0 weeks for fulvestrant and sapanisertib, each).
Drug: Fulvestrant · Drug: Sapanisertib
Fulvestrant IM injection.
Sapanisertib capsule.
Also known as: MLN0128
Progression Free Survival (PFS)
PFS was defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time frame: Up to 40 months
Overall Survival (OS)
OS was defined as the time from the date of randomization to the date of death.
Time frame: Up to 164 weeks
Time to Progression (TTP)
TTP was defined as the time from the date of randomization to the date of first documentation of progression. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time frame: Up to 40 months
Objective Response Rate (ORR)
ORR was defined as the percentage of participants who achieve a best response of complete response (CR) or partial response (PR) according to RECIST v1.1 criteria. CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.
Time frame: Up to 40 months
Clinical Benefit Rate (CBR)
CBR was defined as the percentage of participants who achieved a best response of CR, PR, or stable disease (SD) of any duration. CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Time frame: Up to 40 months
Percentage of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: Up to 164 weeks
Participants took part in the study at 50 investigative sites in Spain and the United States from 28 July 2016 to 25 November 2019. After all data was collected and participants were transitioned to post-trial access, the Sponsor stopped the study site, defined as 'Site terminated by the Sponsor'.
| Milestone | Arm A: Fulvestrant 500 mg | Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD | Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW |
|---|---|---|---|
| Started | 46 | 47 | 48 |
| Treated participants | 46 | 47 | 47 |
| Completed | 0 | 0 | 0 |
| Not completed | 46 | 47 | 48 |
| Withdrew: Site terminated by sponsor | 24 | 30 | 21 |
| Withdrew: Death | 20 | 15 | 18 |
| Withdrew: Withdrawal by patient | 2 | 1 | 8 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 |
PFS was defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
| months | Arm A: Fulvestrant 500 mg | Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD | Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW |
|---|---|---|---|
| Progression Free Survival (PFS) | 3.5 (1.9 to 5.6) | 7.2 (3.9 to 10.6) | 5.6 (4.1 to 9.0) |
OS was defined as the time from the date of randomization to the date of death.
| months | Arm A: Fulvestrant 500 mg | Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD | Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW |
|---|---|---|---|
| Overall Survival (OS) | 30.5 (21.5 to NA) | NA (29.9 to NA) | 34.2 (20.0 to NA) |
TTP was defined as the time from the date of randomization to the date of first documentation of progression. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
| months | Arm A: Fulvestrant 500 mg | Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD | Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW |
|---|---|---|---|
| Time to Progression (TTP) | 3.5 (1.9 to 5.6) | 7.2 (5.5 to 10.6) | 5.6 (4.1 to 9.0) |
ORR was defined as the percentage of participants who achieve a best response of complete response (CR) or partial response (PR) according to RECIST v1.1 criteria. CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.
| percentage of participants | Arm A: Fulvestrant 500 mg | Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD | Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW |
|---|---|---|---|
| Objective Response Rate (ORR) | 10.9 | 21.3 | 12.8 |
CBR was defined as the percentage of participants who achieved a best response of CR, PR, or stable disease (SD) of any duration. CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
| percentage of participants | Arm A: Fulvestrant 500 mg | Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD | Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW |
|---|---|---|---|
| Clinical Benefit Rate (CBR) | 60.9 | 74.5 | 66.0 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
| percentage of participants | Arm A: Fulvestrant 500 mg | Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD | Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW |
|---|---|---|---|
| Percentage of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE) | 89.1 | 100.0 | 100.0 |
Collected over Up to 164 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Fulvestrant 500 mg | 20/46 (43.5%) | 8/46 (17.4%) | 38/46 (82.6%) |
| Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD | 15/47 (31.9%) | 13/47 (27.7%) | 47/47 (100%) |
| Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW | 18/48 (37.5%) | 8/47 (17%) | 47/47 (100%) |
| Event | Arm A: Fulvestrant 500 mg | Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD | Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW |
|---|---|---|---|
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/46 | 0/47 | 0/47 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/46 | 0/47 | 0/47 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/46 | 2/47 | 0/47 |
| Pyelonephritis acuteInfections and infestations | 0/46 | 0/47 | 2/47 |
| VomitingGastrointestinal disorders | 0/46 | 2/47 | 1/47 |
| DiarrhoeaGastrointestinal disorders | 0/46 | 2/47 | 0/47 |
| PyrexiaGeneral disorders | 0/46 | 2/47 | 0/47 |
| PneumoniaInfections and infestations | 1/46 | 0/47 | 0/47 |
| EncephalopathyNervous system disorders | 1/46 | 0/47 | 0/47 |
| HeadacheNervous system disorders | 1/46 | 0/47 | 0/47 |
| Event | Arm A: Fulvestrant 500 mg | Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD | Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW |
|---|---|---|---|
| NauseaGastrointestinal disorders | 9/46 | 23/47 | 41/47 |
| VomitingGastrointestinal disorders | 4/46 | 14/47 | 33/47 |
| HyperglycaemiaMetabolism and nutrition disorders | 10/46 | 27/47 | 26/47 |
| DiarrhoeaGastrointestinal disorders | 1/46 | 24/47 | 13/47 |
| AstheniaGeneral disorders | 11/46 | 13/47 | 21/47 |
| Decreased appetiteMetabolism and nutrition disorders | 5/46 | 15/47 | 19/47 |
| FatigueGeneral disorders | 10/46 | 17/47 | 11/47 |
| StomatitisGastrointestinal disorders | 3/46 | 16/47 | 15/47 |
| PruritusSkin and subcutaneous tissue disorders | 0/46 | 15/47 | 8/47 |
| RashSkin and subcutaneous tissue disorders | 0/46 | 14/47 | 7/47 |
Full Analysis Set included all randomized participants.
| Age, Continuous(years) | Arm A: Fulvestrant 500 mg | Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD | Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW | Total |
|---|---|---|---|---|
| Mean | 60.3 ± 10.10 | 60.3 ± 10.92 | 57.9 ± 12.04 | 59.5 ± 11.05 |
| Sex: Female, Male(Participants) | Arm A: Fulvestrant 500 mg | Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD | Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW | Total |
|---|---|---|---|---|
| Female | 46 | 47 | 48 | 141 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Fulvestrant 500 mg | Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD | Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 4 | 7 | 16 |
| Not Hispanic or Latino | 37 | 41 | 40 | 118 |
| Unknown or Not Reported | 4 | 2 | 1 | 7 |
| Race (NIH/OMB)(Participants) | Arm A: Fulvestrant 500 mg | Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD | Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 | 2 |
| White | 44 | 45 | 44 | 133 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 2 | 3 | 6 |
| Region of Enrollment(Participants) | Arm A: Fulvestrant 500 mg | Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD | Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW | Total |
|---|---|---|---|---|
| Spain | 23 | 34 | 33 | 90 |
| United States | 23 | 13 | 15 | 51 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jul 2016 to primary completion in Nov 2019, 39 months.
Results were first posted in Dec 2020, 1 year after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 39 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sapanisertib